Volcano Reports Second Quarter Results COMPANY ANNOUNCES LITIGATION SETTLEMENT AGREEMENT WITH ST. JUDE MEDICAL AND PLAN TO DIVEST AXSUN TECHNOLOGIES SUBSIDIARY

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, today reported results for the second quarter and first six months of 2014.

The company also announced today that it will be seeking a divestiture of its Axsun Technologies, Inc. subsidiary. In addition, the company said that it and St. Jude Medical, Inc., (NYSE: STJ) have agreed to settle all existing litigation between the two companies.

For the quarter ended June 30, 2014, Volcano reported revenues of $102.6 million versus revenues of $101.3 million in the same period a year ago. Foreign currency exchange rates did not have a material impact on revenues during the quarter.  Medical segment revenues increased approximately two percent on a reported basis.

The company reported net income on a GAAP basis of $282,000, or $0.01 per diluted share, in the second quarter of 2014, versus a net loss of $2.4 million, or $0.04 per share, in the same period a year ago. The results for the second quarter of 2014 included an acquisition-related benefit of $7.2 million related to an adjustment to a contingent liability resulting in a net benefit of $6.4 million, while the results for the second quarter of 2013 included a gain on a strategic investment of $2.2 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported non-GAAP net income of $0.01 per diluted share, compared with non-GAAP earnings per diluted share of $0.03 in the second quarter a year ago.

For the first six months of 2014, Volcano reported revenues of $197.1 million versus revenues of $194.6 million in the first six months of 2013. On a constant currency basis, revenues increased three percent year-over-year after adjusting for a negative impact of approximately $2.7 million from foreign currency. Medical segment revenues increased approximately two and three percent on a reported and constant currency basis, respectively, versus the first six months of 2013.

For the first six months of 2014, the company reported a net loss on a GAAP basis of $10.6 million, or $0.21 per share, versus a net loss of $5.5 million, or $0.10 per share, in the same period a year ago. The results for the first six months of 2014 included a net acquisition-related benefit of $5.4 million, while the results for the first six months of 2013 included other income of $4.2 million. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP net loss of $0.10 per share in the first six months of 2014, compared with non-GAAP net earnings per diluted share of $0.06 in the first six months of 2013.

"Our results for the quarter reflect continued expansion of our IVUS (Intravascular Ultrasound) peripheral business in the U.S. and strong growth for our FFR (Fractional Flow Reserve) disposable business in Japan and Europe," said Scott Huennekens, president and chief executive officer. "These gains helped offset the impact of the continued decline in our coronary IVUS disposable activity."

"The second quarter was highlighted by the acquisition of AtheroMed, Inc., and its Phoenix® Atherectomy System used in the treatment of peripheral artery disease," he continued. "We are on track to initiate a limited market release of the Phoenix device later this year and a full market release in early 2015. In addition, during the quarter we began the roll out of our iFR® (Instant Wave-Free Ratio™) FFR offering and SyncVision™ Co- Registration System in the U.S.," he added. 

With respect to the planned Axsun divestiture, Huennekens said, "This decision was driven by our long-term strategy to focus on coronary imaging and physiology leadership, peripheral expansion, profitability and business scale. The Axsun business and financial model is no longer a strategic fit with Volcano. We greatly appreciate the significant contributions of the Axsun team to Volcano over the past several years."

Under terms of the settlement with St. Jude Medical, the parties have agreed to dismiss their lawsuits with prejudice, with neither party admitting liability to the other. Each party will be granted a release of liability for alleged misconduct, granted a license to all patents-in-suite and granted a covenant not to sue as to various current and future products. As part of the settlement agreement, no financial payments will be made to either party by the other.

"We are pleased with the resolution of these litigation matters and believe this settlement will enable us to better focus on the needs of doctors and patients," Huennekens said.

Guidance

The company provided updated guidance for the full year 2014. Based on current foreign currency exchange rates, it expects revenues on a reported basis will be $397.0-$401.0 million, with revenues on a constant currency basis in the range of $401.0-$405.0 million. The company said it expects gross margins will be in the range of 63.0-63.5 percent and that operating expenses, including restructuring charges, will be 65.5-66.5 percent of revenues. On a reported basis, the company expects a GAAP net loss of $0.52-$0.55 per share.  The company is maintaining its prior guidance for a net loss per share of $0.16-$0.19 on a non-GAAP basis. The company said it has been able to offset its revised outlook for revenues with expense reprioritization initiatives related to SG&A and R&D expenses, resulting in expected lower operating expenses as a percentage of revenues. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 35.0 percent for the GAAP to non-GAAP adjustments. The company expects weighted average basic shares in 2014 will be approximately 51.4 million.

For the third quarter of 2014, Volcano expects revenues in the range of $95.0-$97.0 million on a reported and $95.5-$97.5 million constant currency basis. It expects gross margins will be in the range of 62.0-62.5 percent and that operating expenses will be in the range of 69.0-70.0 percent of revenues. The company expects a net loss per share of $0.17-$0.19 on a GAAP basis and $0.04-$0.06 on a non-GAAP basis.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (631) 291-4555, passcode 66540992, or via the company's website at http://www.volcanocorp.com. Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through August 10, at (404) 537-3406, passcode 66540992, and via the company's website at http://www.volcanocorp.com.

About Volcano Corporation

Through its multi-modality platform, Volcano Corporation is the global leader in intravascular imaging for coronary and peripheral applications, and physiology. The company also offers a suite of peripheral therapeutic devices. The company's broad range of technologies makes imaging and therapy simpler, more informative and less invasive and offers physicians and their patients around the world with industry-leading tools that aid diagnosis and guide and provide therapy. Founded in cardiovascular care and expanding into other specialties, Volcano is focused on improving patient and economic outcomes. For more information, visit the company's website at www.volcanocorp.com.

Note Regarding the Use of Non-GAAP Financial Measures

The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The company uses non-GAAP financial measures for financial and operational decision making as a measure to compare period-to-period results. The company believes that they provide useful information about operating results, enhance the overall understanding of operating results and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Constant Currency Basis Revenue Changes: Volcano reports changes on a constant currency basis, which is a non-GAAP financial measure. Volcano believes that investors' understanding of the company's short-term and long-term financial results is enhanced by taking into consideration the impact of foreign currency translation on revenues. In addition, Volcano's management uses results of operations before currency translation to evaluate the operational performance of Volcano and as a basis for strategic planning.

Volcano reports its expectations of earnings per share performance excluding certain expenses described below; for additional details please see the "Reconciliation of GAAP to non-GAAP EPS Guidance," table in this press release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

Exclusion of Acquisition-Related Expenses: Volcano excludes acquisition-related expenses because it does not consider these acquisition-related costs and adjustments to be related to the continuing organic operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drive the magnitude of acquisition-related costs, may not be indicative of the size, complexity and/or volume of future acquisitions.

Exclusion of Amortization of Intangibles: Volcano excludes amortization of intangibles because it is a non-cash expense relating primarily to acquisitions. At the time of an acquisition, the intangible assets of the acquired company, which consist primarily of developed or in-process technology, are valued and amortized over their estimated lives. Volcano believes that since intangible assets represent efforts of the acquired company to build value prior to the acquisition, Volcano management eliminates the impact of the amortization when evaluating its current operating performance.

Exclusion of Non-Cash Interest Expenses: In addition to disclosing the financial statement impact of the authoritative guidance for convertible debt accounting, Volcano management believes that excluding the impact of this authoritative guidance is appropriate because it is non-cash in nature, may provide meaningful supplemental information regarding elements of the company's borrowing costs in order to properly understand its operational performance and liquidity, and facilitates comparisons to competitors' results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding Volcano's expected revenues, revenue growth, margins, financial results and foreign currency exchange rates for the third and fourth quarter and calendar year 2014, its growth and other strategies and ability to execute on these strategies, the potential Axsun divestiture, competitive position, target markets, development of its base business and pipeline, product launches, benefits from recent acquisitions and benefits from its products and technologies, including new products. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risks that Volcano's revenues or other projections may turn out to be inaccurate or Volcano may encounter unanticipated difficulty in achieving these projections; global and regional macroeconomic conditions, generally, and in the medical device and telecom industries, specifically; currency exchange rate fluctuations; the effect of competitive factors and the company's reactions to those factors; purchasing decisions with respect to the company's products; the pace and extent of market adoption of the company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearances for Volcano's products or devices; the success of Volcano's growth and other strategies, including the integration of recently-acquired businesses and our ability to integrate businesses from potential future acquisitions; risks associated with Volcano's international operations; the ability to divest Axsun, if at all, and in a timely or beneficial manner; timing and achievement of product development milestones; outcome of ongoing and future litigation, investigations or claims; the impact and benefits of market development and the related size of Volcano's addressable markets; our ability to protect our intellectual property; dependence upon third parties; unexpected new data, safety and technical issues; market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are fully described in Volcano's filings made with the Securities and Exchange Commission, including our 10-Q for the quarter ended March 31, 2014, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

 

 

 

 VOLCANO CORPORATION 

 CONDENSED CONSOLIDATED BALANCE SHEETS 

 (in thousands) 

 (unaudited) 






 June 30, 


 December 31, 


2014


2013

 Assets 




 Current assets: 




 Cash and cash equivalents 

$      56,182


$          107,159

 Short-term available-for-sale investments  

149,981


230,775

 Accounts receivable, net 

85,097


81,962

 Inventories 

72,170


60,970

 Prepaid expenses and other current assets 

24,960


28,525

 Total current assets 

388,390


509,391





 Long-term available-for-sale investments 

35,510


34,750

 Property and equipment, net 

122,471


118,094

 Intangible assets, net 

126,970


58,108

 Goodwill 

150,882


55,087

 Other non-current assets 

56,330


56,489

 Total Assets 

$   880,553


$          831,919





 Liabilities and Stockholders' Equity 




 Current liabilities: 




 Accounts payable 

$      13,207


$             19,137

 Accrued compensation 

28,277


26,918

 Accrued expenses and other current liabilities 

29,979


28,453

 Deferred revenues 

11,119


10,652

 Contingent consideration 

14,450


3,750

 Total current liabilities 

97,032


88,910

 Convertible senior notes 

410,868


401,012

 Other long-term debt 

1,208


1,268

 Deferred revenues 

4,802


5,079

 Contingent consideration, non-current portion 

52,984


29,888

 Other non-current liabilities 

6,523


5,960

 Total liabilities 

573,417


532,117

 Stockholders' equity 

307,136


299,802

 Total Liabilities and Stockholders' Equity 

$   880,553


$          831,919

                                                                                                        

 

 

VOLCANO CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)



















Three Months Ended
June 30,



Six Months Ended
June 30,



2014



2013



2014



2013

Revenues


$

102,605



$

101,344



$

197,133



$

194,575

Cost of revenues, excluding amortization of intangibles



37,711




36,039




72,794




69,166

Gross profit



64,894




65,305




124,339




125,409

Operating expenses:
















Selling, general and administrative



49,353




45,734




99,664




89,563

Research and development



13,700




17,954




27,657




33,605

Amortization of intangibles



1,818




820




3,601




1,654

Acquisition related items



(6,441)




911




(5,405)




2,489

Restructuring items



(841)




-




32




-

Total operating expenses



57,589




65,419




125,549




127,311

Operating income (loss)



7,305




(114)




(1,210)




(1,902)

Interest income



281




305




596




643

Interest expense



(7,320)




(6,607)




(14,498)




(13,152)

Exchange rate (loss) gain 



(13)




(301)




71




(1,079)

Other, net



14




2,279




124




4,177

Income (loss) before income tax



267




(4,438)




(14,917)




(11,313)

Income tax benefit



(15)




(2,050)




(4,295)




(5,764)

Net income (loss)


$

282



$

(2,388)



$

(10,622)



$

(5,549)

Net income (loss) per share:
















Basic


$

0.01



$

(0.04)



$

(0.21)



$

(0.10)

Diluted


$

0.01



$

(0.04)



$

(0.21)



$

(0.10)

Shares used in calculating net income (loss) per share:
















Basic



51,300




54,574




51,630




54,389

Diluted



51,674




54,574




51,630




54,389

     

 

 

VOLCANO CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


Six Months Ended
June 30,



2014


2013


Operating activities







Net loss

$

(10,622)


$

(5,549)


Adjustments to reconcile net loss  to net cash used in operating activities:







Depreciation and amortization


15,212



12,223


Amortization of investment premium, net


1,866



1,378


Accretion of debt discount on convertible senior notes and other long-term debt


9,881



9,341


Changes in contingent consideration


(6,204)



1,656


Non-cash stock compensation expense


7,515



7,847


Asset impairment related to restructuring


818



-


Gain on sale of other long-term investment


(365)



(1,925)


Effect of exchange rate changes and others


(953)



9,139


Deferred income taxes


1,014



-


Changes in operating assets and liabilities, net of acquisitions


(20,103)



(32,583)


Net cash (used in) provided by operating activities


(1,941)



1,527


Investing activities







Purchase of short-term and long-term available-for-sale securities


(120,514)



(154,887)


Sale or maturity of short-term and long-term available-for-sale securities


198,621



139,494


Capital expenditures


(14,661)



(18,490)


Cash paid for intangible assets and other investments


(4,941)



(1,692)


Proceeds from sale of other long-term investments


365



3,426


Cash paid for acquisitions, net of cash acquired


(114,791)



-


Net cash used in investing activities


(55,921)



(32,149)


Financing activities







Repayment of capital lease liability


(19)



(15)


Cash paid to settle contingent liability related to acquisition


(2,900)



-


Proceeds from sale of common stock under employee stock purchase plan


1,851



1,713


Proceeds from exercise of common stock options


7,691



1,185


Net cash provided by financing activities


6,623



2,883


Effect of exchange rate changes on cash and cash equivalents


262



(1,136)


Net decrease in cash and cash equivalents


(50,977)



(28,875)


Cash and cash equivalents, beginning of period


107,159



330,635


Cash and cash equivalents, end of period

$

56,182


$

301,760


             

 

VOLCANO CORPORATION

REVENUE SUMMARY

(in millions)

(unaudited)


















Three Months Ended
June 30,


Percentage Change 


Currency Impact 


Constant Currency Percentage Change



2014


2013


2013 to 2014


Dollar

Percentage



Medical segment:
















Consoles:
















United States

$     5.7


$     6.9


(18)

%


$      -


-

%


(18)

%


Japan

0.2


0.1


16



-


(4)



20



Europe

3.1


2.7


17



0.2


6



11



Rest of world

1.2


1.8


(35)



-


-



(35)



Total Consoles

$   10.2


$   11.5


(12)



$   0.2


1



(13)



















IVUS single-procedure disposables:
















United States

$   22.7


$   20.7


10

%


$      -


-

%


10

%


Japan

15.8


20.6


(23)



(0.9)


(4)



(19)



Europe

6.9


6.4


9



0.4


6



3



Rest of world

2.9


2.2


33



-


-



33



Total IVUS single-procedure disposables

$   48.3


$   49.9


(3)



$(0.5)


(1)



(2)



















FFR single-procedure disposables:
















United States

$   15.2


$   15.1


2

%


$      -


-

%


2

%


Japan

5.5


4.4


23



(0.3)


(6)



29



Europe

10.6


8.0


32



0.6


7



25



Rest of world

0.8


1.2


(33)



-


-



(33)



Total FFR single-procedure disposables

$   32.1


$   28.7


12



$   0.3


1



11



















Other

$   10.2


$     8.9


13

%


$(0.1)


(1)

%


14

%


Sub-total medical segment

$100.7


$   99.0


2



$(0.1)


-



2



















Industrial segment

$     1.9


$     2.3


(19)



$      -


-



(19)



Total

$102.6


$101.3


1



$(0.1)


-



1



 

 

VOLCANO CORPORATION

REVENUE SUMMARY

(in millions)

(unaudited)


















Six Months Ended
June 30,


Percentage Change 


Currency Impact 


Constant Currency Percentage Change



2014


2013


2013 to 2014


Dollar

Percentage



Medical segment:
















Consoles:
















United States

$     9.3


$   11.7


(21)

%


$      -


-

%


(21)

%


Japan

1.2


1.1


4



(0.1)


(11)



15



Europe

5.5


4.2


30



0.3


6



24



Rest of world

2.7


3.5


(23)



-


-



(23)



Total Consoles

$   18.7


$   20.5


(9)



$   0.2


1



(10)



















IVUS single-procedure disposables:
















United States

$   43.7


$   40.0


10

%


$      -


-

%


10

%


Japan

32.2


41.3


(22)



(3.2)


(8)



(14)



Europe

13.5


12.2


11



0.6


5



6



Rest of world

5.6


4.4


27



-


-



27



Total IVUS single-procedure disposables

$   95.0


$   97.8


(3)



$(2.6)


(3)



-



















FFR single-procedure disposables:
















United States

$   28.9


$   28.7


1

%


$      -


-

%


1

%


Japan

9.9


8.9


12



(0.9)


(10)



22



Europe

20.0


15.9


26



0.9


5



21



Rest of world

2.0


2.0


-



-


-



-



Total FFR single-procedure disposables

$   60.9


$   55.5


10



$      -


-



10



















Other

$   19.2


$   16.9


13

%


$(0.3)


(2)

%


15

%


Sub-total medical segment

$193.7


$190.7


2



$(2.7)


(1)



3



















Industrial segment

$     3.4


$     3.8


(12)



$      -


-



(12)



Total

$197.1


$194.6


1



$(2.7)


(2)



3



 

 

 

VOLCANO CORPORATION

RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS

(in thousands, except per share data)

(Unaudited)















Three Months Ended June 30, 2014

Pre-tax Adjustments


Net of Tax (1)


Earnings / (Loss) Per Share









 GAAP net income 



$                 282


$                     0.01


 Acquisition related items 

(6,441)


(4,187)


(0.08)


 Amortization of intangibles 

1,818


1,182


0.02


 Non-cash interest expense on convertible notes 

5,011


3,257


0.06


 Non-GAAP net income 

$             388


$                 534


$                     0.01









 Weighted average shares outstanding—diluted 





51,674









Six Months Ended June 30, 2014

Pre-tax Adjustments


Net of Tax (1)


Earnings / (Loss) Per Share









 GAAP net loss 



$        (10,622)


$                   (0.21)


 Acquisition related items 

(5,405)


(3,513)


(0.07)


 Amortization of intangibles 

3,601


2,341


0.05


 Non-cash interest expense on convertible notes 

9,935


6,458


0.13


 Non-GAAP net loss 

$          8,131


$           (5,336)


$                   (0.10)









 Weighted average shares outstanding—basic 





51,630









(1) Effective tax rate of 35% applied to non-GAAP adjustments




           

 

VOLCANO CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP GUIDANCE

(in thousands, except per share data)

(Unaudited)










Q3 2014


Guidance Range


From


To









 GAAP net loss per share—basic 

$  (0.17)


$  (0.19)

 Acquisition related items 

0.03


0.03

 Amortization of intangibles 

0.04


0.04

 Non-cash interest expense 

0.06


0.06

 Non-GAAP net loss per share—basic 

$  (0.04)


$  (0.06)

 Weighted average shares outstanding—basic 

51,415


51,415














2014


Guidance Range


From


To









 GAAP net loss per share—basic 

$  (0.52)


$  (0.55)

 Acquisition related items 

(0.02)


(0.02)

 Amortization of intangibles 

0.12


0.12

 Non-cash interest expense 

0.26


0.26

 Non-GAAP net loss per share—basic 

$  (0.16)


$  (0.19)

 Weighted average shares outstanding—basic 

51,440


51,440









Note: Effective tax rate of 35% applied to non-GAAP adjustments



 

 

 

SOURCE Volcano Corporation



RELATED LINKS
http://www.volcanocorp.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.